Literature DB >> 8537674

Evidence for genetic regulation of susceptibility to toxoplasmic encephalitis in AIDS patients.

Y Suzuki1, S Y Wong, F C Grumet, J Fessel, J G Montoya, A R Zolopa, A Portmore, F Schumacher-Perdreau, M Schrappe, S Köppen, B Ruf, B W Brown, J S Remington.   

Abstract

The frequency of HLA-DQ antigens in AIDS patients with toxoplasmic encephalitis (TE) were examined. HLA-DQ3 was significantly more frequent in white North American AIDS patients with TE (85.0%) than in the general white population (51.8%; P = .007, corrected P = .028) or randomly selected control AIDS patients who had not developed TE (40.0%; P = .016). In contrast, the frequency of HLA-DQ1 was lower in TE patients than in healthy controls (40.0% vs. 66.5%, P = .027), but this difference did not reach statistical significance when corrected for the number of variables tested (corrected P = .108 for the general white population). HLA-DQ3 thus appears to be a genetic marker of susceptibility to development of TE in AIDS patients, and DQ1 may be a resistance marker. These HLA associations with disease indicate that development of TE in AIDS patients is affected by a gene or genes in the HLA complex and that HLA-DQ typing may help in decisions regarding TE prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8537674     DOI: 10.1093/infdis/173.1.265

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

Review 1.  Cardiac involvement with parasitic infections.

Authors:  Alicia Hidron; Nicholas Vogenthaler; José I Santos-Preciado; Alfonso J Rodriguez-Morales; Carlos Franco-Paredes; Anis Rassi
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

2.  Arboprotozoae.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

3.  Impact of spiramycin treatment and gestational age on maturation of Toxoplasma gondii immunoglobulin G avidity in pregnant women.

Authors:  M Lefevre-Pettazzoni; A Bissery; M Wallon; G Cozon; F Peyron; M Rabilloud
Journal:  Clin Vaccine Immunol       Date:  2007-01-03

Review 4.  Effects of Toxoplasma gondii infection on the brain.

Authors:  Vern B Carruthers; Yasuhiro Suzuki
Journal:  Schizophr Bull       Date:  2007-02-23       Impact factor: 9.306

Review 5.  Inflammation and the two-hit hypothesis of schizophrenia.

Authors:  Keith A Feigenson; Alex W Kusnecov; Steven M Silverstein
Journal:  Neurosci Biobehav Rev       Date:  2013-11-15       Impact factor: 8.989

6.  Microsatellite in the beta-tubulin gene of Toxoplasma gondii as a new genetic marker for use in direct screening of amniotic fluids.

Authors:  J M Costa; M L Dardé; B Assouline; M Vidaud; S Bretagne
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

Review 7.  The immune system utilizes two distinct effector mechanisms of T cells depending on two different life cycle stages of a single pathogen, Toxoplasma gondii, to control its cerebral infection.

Authors:  Yasuhiro Suzuki
Journal:  Parasitol Int       Date:  2019-11-25       Impact factor: 2.230

8.  Impaired innate immunity in mice deficient in interleukin-1 receptor-associated kinase 4 leads to defective type 1 T cell responses, B cell expansion, and enhanced susceptibility to infection with Toxoplasma gondii.

Authors:  Samantha R Béla; Míriam S Dutra; Ernest Mui; Alexandre Montpetit; Fernanda S Oliveira; Sérgio C Oliveira; Rosa M E Arantes; Lis R Antonelli; Rima McLeod; Ricardo T Gazzinelli
Journal:  Infect Immun       Date:  2012-10-01       Impact factor: 3.441

9.  Molecular markers of susceptibility to ocular toxoplasmosis, host and guest behaving badly.

Authors:  Adriana Lima Vallochi; Anna Carla Goldberg; Angela Falcai; Rajendranath Ramasawmy; Jorge Kalil; Cláudio Silveira; Rubens Belfort; Luiz Vicente Rizzo
Journal:  Clin Ophthalmol       Date:  2008-12

Review 10.  Modulation of innate immunity by Toxoplasma gondii virulence effectors.

Authors:  Christopher A Hunter; L David Sibley
Journal:  Nat Rev Microbiol       Date:  2012-11       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.